Epilepsy - UK Drug Forecast and Market Analysis to 2022. GlobalData has released its new Country report, PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCBs Keppra and GlaxoSmithKlines Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizers Dilantin, Abbotts Depakote, and Novartis Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the
Original Post PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022
Browse All Reports: Latest Market Research Reports
Browse All Reports: Countrywide Market Research Reports
Browse All Reports: Transparency Market Research Reports
Browse All Reports: Technavio Market Research Reports
Browse All Reports: Winter Green Market Research Reports
Browse All Reports: QY Market Research Reports
Browse All Reports: GBI Market Research Reports
Browse All Reports: Select Biosciences Market Research Reports
Contact: sales@researchmoz.usfor further information.
Hi. I’m Designer of Blog Magic. I’m CEO/Founder of ThemeXpose. I’m Creative Art Director, Web Designer, UI/UX Designer, Interaction Designer, Industrial Designer, Web Developer, Business Enthusiast, StartUp Enthusiast, Speaker, Writer and Photographer. Inspired to make things looks better.
0 comments:
Post a Comment